ElevateBio
30 articles about ElevateBio
-
With the complete acquisition of Life Edit, ElevateBio will be able to integrate that company’s genome editing capabilities with its cell and gene therapies.
-
Boston Children’s Hospital and ElevateBio Announce Five-Year Cell and Gene Therapy Collaboration
6/29/2021
Boston Children’s Hospital and ElevateBio announced that they have entered into a five-year collaborative agreement to advance cell and gene therapy programs originating out of Boston Children’s Hospital with an introduction to Boston Children’s translational research capabilities.
-
The Third Rock Ventures-backed startup has a pipeline of Treg therapeutics aimed at multiple sclerosis, type 1 diabetes and inclusion body myositis.
-
ElevateBio Announces Margo Roberts, Ph.D. Joins as Scientific Advisor for Company’s Immunotherapy Platform Expansion
6/10/2021
Dr. Roberts brings three decades of expertise to further expand ElevateBio's immunotherapy leadership across its protein, viral, and cell engineering technology platforms
-
ElevateBio’s BaseCamp Selected as the 2021 Facility of the Year Award Category Winner for Operational Excellence by the International Society for Pharmaceutical Engineering
4/27/2021
Award recognizes state-of-the-art projects utilizing new, innovative technologies to improve the quality of products, to reduce the cost of producing high-quality medicines, and demonstrate advances in project delivery
-
Money on the Move: March 10-16
3/17/2021
Life sciences money is seemingly growing on trees this year. Here's who picked a good harvest this week. -
ElevateBio Scales Disruptive Cell and Gene Therapy Business Model with $525 Million Series C Financing
3/15/2021
- Proceeds to support the acceleration and scaling of ElevateBio’s end-to-end cell and gene therapy technology platform offering - Series C financing led by Matrix Capital Management, joined by additional new investors SoftBank Vision Fund 2 and Fidelity Management & Research Company alongside ElevateBio’s existing investors
-
Several biotech companies have announced closings of million-dollar financing rounds Monday, with Cambridge, Mass.-based cell and gene therapy company ElevateBio leading the pack. ElevateBio announced it raised $525 million in a Series C financing round, which the company says should help expand ...
-
ElevateBio to Present at the 39th Annual J.P. Morgan Healthcare Conference
1/8/2021
ElevateBio to Present at the 39 th Annual J.P. Morgan Healthcare Conference
-
ElevateBio’s HighPassBio Presents on Novel T Cell Receptor Cell Therapy for Leukemia Relapse at 62nd Annual ASH Meeting
12/6/2020
Adoptive immunotherapy under investigation for children and adults with relapsed acute leukemia after allogeneic hematopoietic stem cell transplantation